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Introduction:We have created a non-human primate (NHP)
model of GvHD. Here we determined whether mTOR inhi-
bition with sirolimus and CD28:CD80/86 costimulation
blockade with belatacept could combine synergistically to
prevent this disease.
Methods: Rhesus macaques were irradiated (9.6 Gy), and
then transplanted with GCSF-mobilized PBSC from a hap-
loidentical donor. Recipients were treated with either siro-
limus alone, belatacept alone or combination therapy.
Clinical GvHD was monitored using an NHP grading scale
and multiparameter ﬂow cytometric analysis (MFC) was
performed.
Results: Untreated controls (n ¼ 5) developed rapid, severe
aGvHD and succumbed rapidly (MST ¼ 7 days). Treatment
with either sirolimus or belatacept alone partially protected
against GvHD. Sirolimus-treated recipients (n ¼ 6) devel-
oped predominantly GI disease and had an MST of 14 days
(Figure 1A). Recipients treated with belatacept alone (n ¼ 3)
developed primarily liver aGvHD and had an MST of 11 days.
In striking contrast, recipients treated with combined siro-
limus + belatacept (n ¼ 5) demonstrated neither uncon-
trolled diarrhea nor hyperbilirubinemia at the timed
terminal analysis (1 month post-transplant).
We used MFC to measure the immunologic consequences
of sirolimus and belatacept on T cell proliferation (Ki-67) and
cytotoxity (granzyme B). While untreated aGvHD was asso-
ciated with rampant CD8+ proliferation (with 83% Ki-67+
CD8+ T cells vs 4.7% pre-transplant), sirolimus or belatacept
monotherapy partially controlled proliferation (35% and 65%
Ki-67+ with sirolimus or belatacept respectively). Combined
sirolimus + belatacept dramatically reduced proliferation (to
8%, favorably comparing with 13% Ki-67+ using tacrolimus/
MTX).
Sirolimus and belatacept also partially controlled T cell
cytotoxicity: While untreated aGvHD was associated
with excessive CD8+ granzyme B expression (82% granzyme
Bvery high vs 0.3% pre-transplant) sirolimus or belatacept
monotherapy partially controlled cytotoxicity (8% and 35 %
granzyme Bvery high with sirolimus or belatacept respec-
tively). Combination therapy dramatically reduced granzyme
Bvery high expression, to 1.5%, favorably comparing with 4%
using CNI/MTX.
The ability of sirolimus, belatacept, or the combination to
control Ki-67 and Granzyme B expression closely correlated
with survival (Figure 1B,C), and signiﬁcant co-expression of
granzyme B in the Ki-67+ cells was observed (Figure 1D),
suggesting that dual-positive Ki-67/Granzyme B cells may
mark a pathogenic population, amenable to tracking in the
peripheral blood.Implications: These results show, for the ﬁrst time, that
sirolimus and belatacept can combine synergistically to
control primate aGvHD. They also identify CD8+/Ki-67+/
Granzyme Bvery high dual-positive T cells as a potentially
sensitive biomarker of GvHD pathogenesis, amenable to
monitoring longitudinally in the blood.
Figure 1. Synergistic Control of Acute GvHD With Sirolimus + belatacept
(A) Dual therapy with sirolimus + belatacept synergistically prolongs survival
in a NHP aGvHD model.
(B) Proliferation, measured by Ki-67+ CD8+ T cells, correlates with clinical
aGvHD severity.
(C) Cytoxicity, measured by Granzyme B expression in CD8+ T cells, correlates
with clinical aGvHD severity.
(D) Signiﬁcant co-expression of KI-67 and Granzyme B in pathogenic CD8+ T
cells.
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Chronic graft versus host disease (cGvHD) remains
a major complication of allogeneic hematopoietic stem cell
transplantation (HSCT). At present, the immunopathophysi-
ology of cGVHD is not fully understood. A number of pre-
clinical and clinical studies support a role for B cell involve-
ment in the pathogenesis of cGvHD. Increased numbers of
CD21- B cell, believed to be immature/ transitional B cells,
were recently reported in the peripheral blood (PB) of cGvHD
patients. In this study, we report the expansion of a CD21- B
cell populationwith an exhausted phenotype in the memory
B cell compartment of patients with active cGVHD. Using
multicolor ﬂow cytometry we performed an extensive
anaylsis of B phenotype and function in 16 patients with
active cGvHD compared to 14 age-matched HSCT recipients
without clinical evidence of cGVHD and 11 healthy controls.
Chronic GvHD patients had signiﬁcantly higher frequencies
of CD21- B cells in the PB compared with patients without
cGvHD and HC (median 12.2% vs. 2.12% vs. 3%; P < 0.01).
Multi-parameter ﬂow cytometry revealed that the majority
of these cells were CD10- CD27- CD21‑ CD20hi, reminiscent
of the recently described exhausted B cells in HIV
patients with chronic viremia. We did not observe increased
transitional (CD24hi-CD38hi- CD19+) or immature B cells
(CD10+CD21-CD27-CD19+) in cGvHD patients compared with
patients with no cGVHD (median transitional 3.4% vs. 6.3%;
p¼0.08) and (median immature (out of total CD21- B cells)
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expanded CD21- B cells in cGVHD patients also expressed
higher inhibitory receptors namely FCRL4, CD22 and CD85J,
chemokine receptors CD11c, CXCR3 and lower CD62L and
CCR7 compared with naïve (CD27-CD21+CD19+) and clas-
sical memory CD27+CD21+CD19+) B cells. Moreover, B cells
in patients with cGVHD had a lower proliferative potential
following B-cell receptor crosslinking compared with B cells
from patients with no GvHD or HC, a feature of exhaustion
associated with high expression of inhibitory receptors.
Finally, the frequencies of circulating CD21- B cells correlated
with cGvHD grade (r¼0.67; P ¼ .002) but not with time from
SCT (r¼0.28; P ¼ .15). These data suggest that CD21- B cells
may play a role in the pathogenesis of cGVHD and could be
used as as a marker of disease severity.55
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Chronic graft-versus-host disease (cGVHD) remains
a complication of allogeneic HCT and treatment remains
prednisone dependent with starting dose of 1mg/kg/day.
Rituximab shows efﬁcacy in steroid-refractory cGVHD sup-
porting B-cell pathogenesis. We hypothesized that anti-B cell
therapy delivered at cGVHD development is effective and
steroid-sparing. 35 patients (pts) with new-onset cGVHD,
requiring systemic steroid treatment at 1mg/kg/day, received
Rituximab 375-mg/m2 weekly x4 within ﬁrst month of
diagnosis. A second course was allowed if pts had less than
a partial response (PR) after 2 months.
Primary endpoints were six-month and 1y clinical
responses including steroid requirements. All 35 pts are
evaluable with 1.5y follow-up. Clinically meaningful
responses (deﬁned as pts with a PR or CR and prednisone
<0.25 mg/kg/day) were seen in 15/35 pts (43%, 13 CR; 2 PR)
at 6 months and remained 15/35 (43%, 11 CR, 4 PR) through
1y. There were 6 deaths from cGVHDwithin 1y of Rituximab.Table 1
Clinically meaningful responses (CR or PR and prednisone <0.25 mg/kg)
Responde
Median days to cGVHD 233 (136-
Pre-ritux CD19+ B cells/microliter 110 (rang
Pre-ritux naïve CD19+ CD38-, IgD+ CD27- B cells/
microliter
102 (0-11
Recovery of naïve B cells 1.5 y after Rituximab/microliter 63 (0-43
Pre-ritux IgG (mg/dl) 645 (224-
Pre-ritux BAFF (mg/dl) 2.8 (0.8-8
F/M pairs
n¼15
11 (73%)
9/15 FàM tested HY IgG positive preRitux All 11 res
became
seronegatOverall, cGVHD clinical response was predicted by naïve
CD19+CD38-IgD+CD27- B-cells pre-rituximab (p¼0.03), and
low BAFF (p¼0.007). B-cell-alloreactivity was assessed by HY
IgM, IgG, and HY speciﬁc B-cell quantiﬁcation. 15 cGVHD
patients were male with female donors (F/M) and 6 (38%)
tested HY IgM positive and 9 (56%) were HY IgG positive at
cGVHD diagnosis. Both HY IgM and IgG became undetectable
in all responders. In contrast, 3 of the 4 nonresponders
remained IgG HY positive and the other 1 redeveloped HY
IgG with cGVHD progression. Similarly, HY-antigen speciﬁc
B-cells were detected in 8/15 (53%) before rituximab and
recurred in 4/6 survivors with progression of cGVHD thus far.
This ﬁrst reported clinical trial of Rituximab and cortico-
steroids for new-onset cGVHD showed 46% clinically mean-
ingful responses through 1y with a steroid sparing effect. The
redevelopment of alloreactive B cells and HY IgG in associ-
ation with cGVHD progression suggests longer Rituximab
treatment-schedules or more potent B-cell inhibitors may
further improve cGVHD therapy.
56
Regulation of Apoptotic Pathways in Human Regulatory
T Cells in Chronic Graft Versus Host Disease (cGVHD) After
Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT)
Kazuyuki Murase, Yutaka Kawano, Jeremy Ryan,
Ken-ichi Matsuoka, Gregory Bascug, Sean M. McDonough,
Robert Smith, Suzan Lazo-Kallanian, John Daley, John Koreth,
Robert J. Soiffer, Anthony Letai, Jerome Ritz. Hematologic
Malignancies, Dana-Farber Cancer Institute, Boston, MA
CD4+CD25+Foxp3+ regulatory T cells (Treg) play a central
role in the maintenance of immune tolerance. Impaired
recovery of Treg after HSCT is associated with the develop-
ment of cGVHD. In patients with cGVHD, Treg proliferate at
high levels but these cells are also highly susceptible to
apoptosis, leading to decreased survival and relative Treg
deﬁciency. To identify mechanisms that regulate Treg
susceptibility to apoptosis we used a new ﬂow cytometry-
based assay to measure mitochondrial membrane depolar-
ization in response to a panel of pro-apoptotic BH3 peptides
(BIM, BID, BAD, NOXA, PUMA, BMF, HRK). This allowed us to
compare BH3 peptide-induced mitochondrial membrane
depolarization (“priming”) in different T cell subsets; CD4
Treg, conventional CD4 T cells (CD4 Tcon), and CD8 T cells.
We also examined cytoplasmic expression of Bcl-2, Mcl1,
BclxL, Bim and cell surface expression of CD95 death receptor
(Fas). Functional susceptibility to apoptosis was measured
following in vitro stimulation with staurosporine or anti-rs n¼15 Nonresponders n ¼17 P-value
988) 245 (138-357) ns
e 0-1723) 299 (14-1140) 0.09
58) 58 (0-700) 0.03
0) 8 (0-33) 0.05
1800) 547 (242-1410) ns
) 7.3 (1-15.5) p¼0.007
4 (27%) p¼0.01
ponders
ive
3 remained HY
positive;
one redeveloped HY
IgG
